UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Nature (London), 2014-11, Vol.515 (7528), p.558-562

2014

Volltextzugriff (PDF)

Liposome-encapsulated curcumin : In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

Cancer, 2005-09, Vol.104 (6), p.1322-1331

2005

Volltextzugriff (PDF)

Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors

Cancer, 2023-06, Vol.129 (12), p.1919-1929

2023

Volltextzugriff (PDF)

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Lung cancer (Amsterdam, Netherlands), 2015-09, Vol.89 (3), p.357-359

2015

Volltextzugriff (PDF)

Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial

European journal of cancer (1990), 2018-12, Vol.105, p.71-78

2018

Volltextzugriff (PDF)

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Volltextzugriff (PDF)

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

The lancet oncology, 2023-05, Vol.24 (5), p.496-508

2023

Volltextzugriff (PDF)

Liposome‐encapsulated curcumin

Cancer, 2005-09, Vol.104 (6), p.1322-1331

2005

Volltextzugriff (PDF)

A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600 -mutated solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3098-3098

2023

Volltextzugriff (PDF)

EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3647-TPS3647

2020

Volltextzugriff (PDF)

Real-world persistence and adherence with oral trifluridine/tipiracil or regorafenib in patients with colorectal cancer

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.49-49

2022

Volltextzugriff (PDF)

Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3523-3523

2021

Volltextzugriff (PDF)

Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4046-4046

2024

Volltextzugriff (PDF)

Phase I results from a phase 1/2 multi-center study of nab -sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16050-e16050

2020

Volltextzugriff (PDF)

A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS3144-TPS3144

2021

Volltextzugriff (PDF)

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT125-CT125

2020

Volltextzugriff (PDF)

Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT165-CT165

2020

Volltextzugriff (PDF)

Comparative effectiveness and resource utilization of nab -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer management and research, 2017-01, Vol.9, p.141-148

2017

Volltextzugriff (PDF)

Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5509-5509

2021

Volltextzugriff (PDF)

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5550-5550

2021

Volltextzugriff (PDF)

Real-world analysis of treatment patterns examining nab -Paclitaxel plus Gemcitabine ( nab -P+G) versus FOLFIRINOX (FFX) in first-line (1L) treatment (tx) of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18130-e18130

2016

Volltextzugriff (PDF)

Real-world analysis of treatment patterns examining nab -Paclitaxel plus gemcitabine ( nab -P+G) versus gemcitabine monotherapy (G) in first-line treatment of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e18100-e18100

2016

Volltextzugriff (PDF)

Comparative effectiveness of early-line nab -paclitaxel ( nab -P) versus eribulin in patients (pts) with metastatic breast cancer (MBC): A U.S. real-world analysis

Journal of clinical oncology, 2016-03, Vol.34 (7_suppl), p.293-293

2016

Volltextzugriff (PDF)

1 – 25 von 180

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(164)

Publikationsform

Sprache

Englisch
(180)

Erscheinungsjahr

n.n

Thema

Science & Technology
(61)
Life Sciences & Biomedicine
(60)
Humans
(55)
Oncology
(46)
Male
(39)
Female
(36)
Middle Aged
(36)
Aged
(29)
Adult
(27)
Tumors
(19)
Aged, 80 And Over
(15)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Neoplasms - Drug Therapy
(12)
Patients
(11)
Treatment Outcome
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
Chemotherapy
(10)
Cancer
(8)
Antineoplastic Agents - Therapeutic Use
(7)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Liposome-encapsulated curcumin : In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Liposome‐encapsulated curcumin

A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600 -mutated solid tumors

EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors

Real-world persistence and adherence with oral trifluridine/tipiracil or regorafenib in patients with colorectal cancer

Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma

Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202

Phase I results from a phase 1/2 multi-center study of nab -sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss

A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress)

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort

Comparative effectiveness and resource utilization of nab -paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: Data from phase 1 and phase 2 studies

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC)

Real-world analysis of treatment patterns examining nab -Paclitaxel plus Gemcitabine ( nab -P+G) versus FOLFIRINOX (FFX) in first-line (1L) treatment (tx) of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting

Real-world analysis of treatment patterns examining nab -Paclitaxel plus gemcitabine ( nab -P+G) versus gemcitabine monotherapy (G) in first-line treatment of metastatic pancreatic adenocarcinoma (MPAC) in a U.S. community oncology setting

Comparative effectiveness of early-line nab -paclitaxel ( nab -P) versus eribulin in patients (pts) with metastatic breast cancer (MBC): A U.S. real-world analysis

Suchergebnisse filtern